NanoDerm Pharma biotech company, the cofounder of which is RVC Seed Fund’s portfolio company NanoDerm Profi, became a resident of Skolkovo Innovation Center. NanoDerm Pharma Company has been included in the Biomedical Technologies Cluster of the Skolkovo Fund. It will develop new medical products based on transdermal nanosystems aimed to treat diseases of the joints and musculoskeletal system, as well as vertebral and atherosclerotic vascular diseases.
It is encouraging that one more project submitted by one of RVC Seed Fund’s portfolio companies received a positive evaluation from the Skolkovo Fund experts and became a resident of the innovation center – the General Director of NanoDerm Profi Marina Nekrylova says. - We are convinced that the preferences provided to Skolkovo resident companies will allow us to significantly optimize the company's business plan and enhance competitive advantage of our production.
The NanoDerm Profi project shows rapid growth, - Alexey Teleshev says, the director of RVC Seed Fund, LLC. - RVC Seed Fund has participated in two funding rounds of NanoDerm Profi Company for the last two years. Technologies developed by the company are demanded in the market of biotech and pharmaceutical transportation systems. We believe that NanoDerm Pharma will develop as quickly and successfully as its parent company.